Panther Fusion® Flu A/B/RSV Assay

A fully-automated approach to testing of influenza A (Flu A), influenza B (Flu B) and respiratory syncytial virus (RSV) in one single assay.1

Assay box in lab background

    Overview

    Documents

    Training

    Respiratory Testing & Patient-Specific Results

    Respiratory viruses are responsible for a wide range of acute respiratory tract infections including the common cold, influenza, and croup and represent a common cause of acute illness.1,2 Disease severity can be especially high in the young, the immunocompromised, and elderly patients.1

    Increase Efficiency & Reduce Costs

    Accurate and timely diagnosis of the cause of respiratory tract infections has a number of benefits for patients and their communities.

    Reduces Complications

    Helps reduce the potential for further development of antimicrobial resistance due to antibiotics.2,3

    Patient Care First

    Potential to improve patient care and helps decrease costs.2-4

    Results with Purpose

    Provides valued information to public health authorities regarding which viruses are circulating in the community.2,5

    Helps Minimise Spread

    Assists infection control personnel to provide appropriate measures to minimise nosocomial spread.2,6

    Simplify & Scale the Future of Diagnostics

    The Panther Fusion Flu A/B/RSV Assay is part of the Hologic Molecular Scalable Solution, a portfolio combining a broad, high-performing assay menu with high-throughput automation. Designed to flexibly scale to meet your needs, from a single patient result to population-level screening.

    Technician walking through Panther systems in a lab setting

    Be Prepared for the Winter Respiratory Season

    The Panther Fusion assay shows excellent clinical performance.1

    98.8% Sensitivity

    99.0% specificity Influenza A

    100% Sensitivity

    99.8% specificity Influenza B

    99.3% Sensitivity

    90.0% specificity RSV

    Right Patient. Right Test. Right Time.7

    • From true on-demand testing to high-throughput
    • No sample batch constraints, prioritise urgent samples
    • First results in 2.4 hours
    • Run multiple assays from a single specimen tube at the same time
    • Single dose, ready-to-use-assay reagent cartridge
    • Long onboard stability of fluids and reagents
    Lab technician carrying a tray of specimens to insert into Panther system
    Lab technician pressing buttons on monitor

    Verified Sample Collection

    The Panther Fusion Flu A/B/RSV assay is validated for nasopharyngeal swabs in viral transport medium and universal transport medium.1

    Evidence. Insight. Collaboration.

    Our education portal improves patient care through excellence in education, communication of clinical and scientific evidence, and partnerships with the healthcare community.

    Insights

    Healthcare provider looking at scan images on monitor display

    FDA Market Authorisation for Genius™ Digital Diagnostics System

    Cervical screening infographics

    Discover the Future of Cervical Cancer Screening

    A Vision for Women-centric Care

    A Vision for Women-centric Care

      1. Panther Fusion Flu A/B/RSV Assay [package insert]. AW-23081 Rev. 001. San Diego, CA: Hologic, Inc.; 2022. 
      2. Troeger C. et al GBD 2016 Lower Respiratory Infections Collaborators. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Infect Dis. 2018 Nov;18(11):1191-1210. doi: 10.1016/S1473-3099(18)30310-4. Epub 2018 Sep 19. PMID: 30243584; PMCID: PMC6202443.
      3. Pinsky BA, Hayden RT. Cost-Effective Respiratory Virus Testing. J Clin Microbiol. 2019 Aug 26;57(9):e00373-19. doi: 10.1128/JCM.00373-19. PMID: 31142607; PMCID: PMC6711893.
      4. https://www.health.vic. gov.au/health-advisories/testing-for-respiratory-pathogens Accessed August, 2022.
      5. WHO-2019-nCoV-Surveillance-Guidance-2022.1-eng.pdf https://www.who.int/publications/i/item/WHO-2019-nCoV-SurveillanceGuidance-2022.2 Accessed October, 2022.
      6. Lim RHF, Htun HL, Li AL, Guo H, Kyaw WM, Hein AA, Ang B, Chow A. Fending off Delta - Hospital measures to reduce nosocomial transmission of COVID-19. Int J Infect Dis. 2022 Apr;117:139-145. doi: 10.1016/j.ijid.2022.01.069. Epub 2022 Feb 4. PMID: 35124240; PMCID: PMC8813202.
      7. Panther/Panther Fusion System Operator´s Manual. AW-26055-001 Rev 001, San Diego, CA: Hologic Inc.; 2022.

      2797

      Hologic BV, Da Vincilaan 5, 1930 Zaventem, Belgium.

      Notified Body number wherever applicable

      EC Representative Information wherever applicable